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ABSTRACT 
Background: tAnGo, an international phase III trial, was designed to evaluate the 
potential role of gemcitabine when added to anthracycline and taxane-containing 
adjuvant chemotherapy for early breast cancer (EBC). At the time the study was 
developed gemcitabine had shown significant activity in metastatic breast cancer, 
and there was evidence of a favourable interaction with paclitaxel. 
Methods: tAnGo entered women of 18 years or older, with newly diagnosed, early 
stage breast cancer who had a definite indication for chemotherapy, any nodal 
status, any hormone receptor status, and adequate marrow, hepatic and renal 
function. tAnGo was a randomised phase 3, open-label, superiority trial. The primary 
endpoint was disease-free survival (DFS) and the trial aimed to detect 5% 
differences in 5-year DFS rates between EC-GT (4 cycles of epirubicin 90mg/m2 IV 
(E) and cyclophosphamide 600mg/m2 IV (C) day1 every (q) 3 weeks, followed by 4 
cycles of paclitaxel 175mg/m2 /3hour infusion (T) day1 with gemcitabine 1250mg/m2 
IV (G) days1 and 8, q3 weeks) and EC-T. Overall survival (OS) was a secondary 
endpoint. Patients were randomised by a central computerised deterministic 
minimisation procedure, with stratification by country, age, radiotherapy intent, nodal 
status, oestrogen (ER) and HER2 receptor status. Recruitment completed in 2004 
and this is the final, intention-to-treat analysis. This trial is registered with EudraCT 
(2004-002927-41), ISRCTN (51146252), and ClinicalTrials.gov (NCT00039546). 
Results: Between August 2001 and November 2004, 3152 patients were 
randomised from the UK and Ireland, by 127 centres; 1576 to EC-GT, and 1576 to 
EC-T. Patient characteristics were balanced across treatment groups: 77% node 
positive, 55% <50 years old, 62% of tumours grade 3, 63% >2cm, 44% ER negative, 
50% PgR negative, 13% HER2 positive. This protocol-specified final analysis has a 
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median follow-up of 10 years (IQR 10-10 years) and recorded 1087 DFS events and 
914 deaths. No statistically significant difference between treatments was observed 
in DFS (adjusted HR=0·97 (95%CI 0·86-1·10) p=0·64) or OS (adjusted HR=1·02 
(95%CI 0·89-1·16) p=0·81). No benefit for EC-GT was found in any of the protocol-
determined subgroups. Toxicity, dose intensity and a detailed safety sub-study 
showed both regimens to be safe, deliverable and tolerable. Grade 3 and 4 toxicities 
were reported at expected levels in both groups. Most commonly suffered (in 1565 
EC-GT pts vs 1567 EC-T pts respectively) were neutropenia (Grade 3: 323 (21%) vs 
212 (14%); Grade 4: 204 (13%) vs 200 (13%)): muscle and joint pains (Grade 3: 200 
(13%) vs 175 (11%); Grade 4: 7 (<1%) vs 11 (1%)): fatigue (Grade 3: 198 (13%) vs 
140 (9%); Grade 4: 9 (1%) vs 12 (1%)): infection (Grade 3: 194 (12%) vs 131 (8%); 
Grade 4: 8 (1%) vs 10 (1%)): vomiting (Grade 3: 134 (9%) vs 101 (6%); Grade 4: 9 
(1%) vs 7 (1%)): nausea (Grade 3: 132 (8%) vs 102 (7%)). 
Interpretation: The addition of gemcitabine to anthracycline and taxane-based 
adjuvant chemotherapy at this dose and schedule confers no therapeutic advantage 
in terms of DFS and OS in early breast cancer although it did cause more toxicity. 
Therefore gemcitabine has not been added to standard adjuvant chemotherapy in 
breast cancer for any subgroup. 
 
Funding: Cancer Research UK core funding for Clinical Trials Unit, University of 
Birmingham, Eli Lilly, Bristol-Myers Squibb, and Pfizer. 
 
 
Key Words: tAnGo, early breast cancer, adjuvant chemotherapy, EC-T, 
gemcitabine. 
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INTRODUCTION 
Despite the therapeutic advances of the last three decades, the development of 
more effective adjuvant therapy remains a priority for improving the treatment of 
women with early breast cancer The modest impact of traditional adjuvant 
polychemotherapy (mainly cyclophosphamide, methotrexate, 5-fluoruracil [CMF]) 
had been confirmed as a 24% global reduction in the risk of relapse or death (hazard 
ratio (HR)=0·76) and a 15% reduction in the risk of death (HR=0·85) in the meta-
analysis by the Early Breast Cancer Trialists Collaborative Group1. The incorporation 
of anthracyclines provided additional benefits, with an estimated HR for relapse or 
death of 0·88 compared with CMF1, and a HR  0·7 in individual trials with higher 
dose epirubicin-based adjuvant regimens2-4. Following the routine inclusion of 
anthracyclines into standard adjuvant treatment, both the CALGB 93445 and NSABP 
B286 trials showed that the sequential addition of four cycles of paclitaxel to standard 
therapy with four cycles of doxorubicin and cyclophosphamide further reduced the 
risk of recurrence. CALGB 9344 reported that the risk of relapse or death was 
reduced by 17% (HR=0·83 (95%CI 0·73-0·94), p=0·0013) and the risk of death by 
18% (HR=0·82, (0·71-0·95), p=0·0061)5 The NSABP B28 trial confirmed a HR=0·83 
(0·73-0·95), p=0·008) for relapse or death and a non-significant improvement in 
overall survival. A meta-analysis of polychemotherapy conducted by the EBCTCG 
confirmed the benefits of the addition of taxanes to anthracycline-based 
polychemotherapy regimens7. 
 
Based on pre-clinical evidence of a potentially favourable interaction between 
paclitaxel and gemcitabine, and the favourable results of a pivotal randomised phase 
III trial comparing paclitaxel and gemcitabine in combination against single agent 
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paclitaxel in patients who had anthracycline pre-treated metastatic disease, it 
seemed plausible that the addition of gemcitabine to paclitaxel in the anthracycline / 
cyclophosphamide (AC-T) regimen might further improve DFS and OS in early stage 
disease. The tAnGo trial was designed to evaluate the addition of gemcitabine to a 
sequential epirubicin and cyclophosphamide followed by paclitaxel regimen. The 
only other adjuvant trial in breast cancer testing the addition of gemcitabine to 
standard chemotherapy was NSABP-B388, a three arm trial with gemcitabine added 
to doxorubicin /cyclophosphamide and paclitaxel (AC-TG). 
 
The tAnGo trial was one of the first breast cancer trials to have a ‘companion’ 
neoadjuvant study (Neo-tAnGo) which reported in 20149. Both the endpoint of 
pathological complete response (pCR) from the Neo-tAnGo trial, which directly tests 
the chemo-sensitivity of the combination on the primary tumour, and the long term 
outcomes of DFS and OS from the tAnGo trial reported in this manuscript, are now 
available. 
 
A preliminary safety analysis without outcome data on the first 135 patients reported 
in 2008, demonstrated that both regimens were well tolerated, with only temporary 
changes in pulmonary function and transaminitis10. The preliminary results of tAnGo 
were presented as a conference abstract in 2008 at a median of 3 years follow-up11, 
and showed no benefit from the addition of gemcitabine (DFS HR=1·0 (95%CI 0·8-
1·2), p=0·96, OS HR=1·1 (95%CI 0·9-1·4), p=0·35). The present manuscript 
provides the only definitive and final analysis of the trial. All tAnGo patients were 
randomised more than 10 years ago, and we report here the long-term results for 
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DFS and OS at a median follow-up of 10 years (IQR 10-10 years) alongside the 5- 
and 10-year detailed safety study findings. 
 
METHODS 
Study design and participants 
The tAnGo phase III randomised trial was designed to test the hypothesis that the 
addition of gemcitabine to the second phase of a standard regimen of epirubicin and 
cyclophosphamide followed by paclitaxel (EC-GT) improves disease-free survival 
(DFS) in comparison to epirubicin and cyclophosphamide followed by paclitaxel 
alone (EC-T) in women with early stage breast cancer with a definite indication for 
adjuvant chemotherapy. 
 
We enrolled women aged 18 years or older with completely excised invasive early 
breast cancer of any nodal or hormone receptor status. Patients were enrolled where 
according to risk, a definite indication for adjuvant chemotherapy existed. This 
included ER negative (defined as Allred score 0-2); ER weakly positive (Allred score 
3-5); and grade 3 tumours, and in these categories recruitment was regardless of 
nodal status. Patients with ER strongly positive (Allred Score 6-8) or grade I or II 
tumours were usually included only if positive axillary lymph nodes were present. 
Other eligibility criteria included adequate bone marrow, hepatic, and renal function, 
adequate (0-1) ECOG performance status, no previous exposure to chemotherapy 
or radiotherapy, no previous or concomitant cancer, the ability to commence 
chemotherapy within 8 weeks of surgery, and written informed consent. Women 
were enrolled at 127 sites in the UK and 2 in Ireland. 
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At the start of the trial, eligibility criteria stated that tumours must be either ER-
negative (defined as Allred score 0-2) or weakly positive (Allred score 3-5) and, in 
the case of weakly ER-positive breast cancer, these must be either PgR-negative or 
weakly positive (Allred score 3-5). In 2003, after 550 patients had been recruited, the 
protocol was amended and these initial criteria were relaxed to include patients with 
any hormone receptor status, given the evidence that was accruing during the trial 
recruitment phase, for taxane activity irrespective of hormone receptor status. Full 
eligibility can be found in the trial protocol. 
 
After completion of trial therapy, the guidance was that all ER-positive patients 
should receive 5 years of adjuvant treatment (tamoxifen or an aromatase inhibitor) 
either within another trial or as standard treatment. The protocol anticipated both 
clinical trials of other hormonal therapy and tamoxifen duration beyond 5 years. 
Patients had follow-up usually carried out by oncologists and this was advised at 
appropriate intervals for the higher risk patients included in the trial. These follow-up 
intervals allowed accurate and timely capture of relapse events, as well as allowing 
proper documentation of toxicity and its resolution. After completion of trial treatment 
follow-up intervals were 3-monthly for 6 months, then 6-monthly for 3 years, and then 
annually to ten years after diagnosis. 
 
The tAnGo trial was an investigator designed and led trial, approved by the MHRA 
on 06-Sep-2000, the West Midlands Multi-Centre Research Ethics Committee on 11-
Dec-2000 and by all Local Research Ethics Committees and Research and 
Development Departments at participating hospitals. The trial was centrally 
coordinated by the Cancer Research UK Clinical Trials Unit, University of 
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Birmingham with regional coordination being provided by the Clinical Trials Research 
Unit, University of Leeds, the ISD Cancer Clinical Trials Team, Partner in CaCTUS in 
Edinburgh and Cancer Trials Ireland (formerly the All Ireland Cooperative Oncology 
Research Group - ICORG), Dublin, Ireland. Statistical support was provided by 
Warwick Clinical Trials Unit, University of Warwick. 
 
Randomisation and masking 
The open-label tAnGo trial used a central computerised deterministic minimisation 
procedure to randomise patients (1:1) between EC-GT and EC-T treatment regimens 
(Figure 1). Treatment allocation was made by telephone to one of the three regional 
trials offices (Birmingham, Leeds or Edinburgh). Stratification was by country 
(England, Scotland, Wales, Republic of Ireland, Northern Ireland), age (<=50, >50 
years old), radiotherapy intent (planned, not planned), nodal status (negative, 1-3 
nodes positive, 4+ nodes positive), ER status (negative, weakly positive, strongly 
positive) and HER2 status (3+, other [0, 1+, 2+], unknown).  
 
Procedures 
The primary endpoint was disease-free survival and secondary endpoints were 
overall survival, toxicity, delivered dose-intensity, tolerability and serious adverse 
events and were all investigator assessed and reported to the University of 
Birmingham CRCTU. For all patients adverse events were recorded for each 
chemotherapy cycle according to Common Terminology Criteria for Adverse Events 
(CTCAE) v2·0 grade. 
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Control arm chemotherapy was epirubicin 90mg/m2 IV with cyclophosphamide 
600mg/m2 IV day1 every (q) 3 weeks for 4 cycles, followed by paclitaxel 
175mg/m2/3hour infusion day1 q 3 weeks for 4 cycles (EC-T). Investigational arm 
chemotherapy was the same with the addition of gemcitabine 1250mg/m2 IV days1 
and 8 q3 weeks to the paclitaxel (EC-GT). 
 
If neutropenic fever or sepsis occurred after a cycle of chemotherapy, the next cycle 
was delayed until the absolute neutrophil count was at least 1·0 × 10⁹ cells per L. 
Following a delay, either dose reduction of all drugs to 80%, or GCSF support with 
100% dose were allowed, and all remaining cycles of the same four-cycle block were 
given at those doses. For persistent thrombocytopenia, the next cycle was delayed 
until patients had at least 100 × 10⁹ platelets per L and was reduced to 80%, 
maintaining this dose reduction for subsequent cycles. Primary prophylaxis with 
GCSF was not provided with either epirubicin and cyclophosphamide or paclitaxel 
(with or without gemcitabine). Once started, prophylactic GCSF was usually 
continued into the second phase of chemotherapy at the discretion of the 
responsible physician. Day 8 FBC values had no impact on treatment decisions. 
 
If grade 2 neuropathy occurred during treatment with paclitaxel, remaining doses 
were reduced to 135 mg/m² (gemcitabine was unchanged). If grade 3 neuropathy 
occurred, either gemcitabine continued alone or trial chemotherapy was 
discontinued. 
 
Gemcitabine was dose-reduced to 80% in the event of grade 3 hepatic toxicity 
(transaminitis; aspartate aminotransferase or alanine aminotransferase ≥5–20 × 
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upper limit of normal [ULN]) on day of treatment at clinician’s discretion, because 
transaminitis is not known to affect gemcitabine clearance. We were unable to 
substantiate earlier concerns about gemcitabine’s potential for clinically significant 
hepatic impairment. In the event of gemcitabine-related pulmonary toxicity of CTCAE 
grade 2 or worse, the patient was discontinued from study therapy. 
 
Cardiac toxicity was not anticipated at the cumulative epirubicin dose of 360 mg/m² 
but if congestive cardiac failure developed, patients were investigated and treated as 
appropriate, epirubicin was discontinued, and other chemotherapy was given at the 
discretion of the treating clinician. 
 
For allergic reactions to paclitaxel, the infusion was stopped if mild symptoms of skin 
rash, flushing, and localised pruritus occurred (Grade 1 and 2). Intravenous steroids 
and antihistamines were given and immediate slow re-challenge of chemotherapy 
was used on recovery. Paclitaxel infusion was stopped if moderate symptoms of 
generalised pruritus or rash, mild dyspnoea, or mild hypotension occurred and 
intravenous steroids and antihistamines were given (Grade 3). 48 h of steroids were 
then advised before cautious paclitaxel re-challenge. If severe symptoms occurred, 
including bronchospasm, generalised urticaria, angio-oedema, hypotension (systolic 
blood pressure <100 mm Hg), or life-threatening anaphylaxis (Grade 4), paclitaxel 
infusion was stopped and treatment was given with intravenous steroids, and 
intravenous antihistamines and if necessary intramuscular epinephrine 1 mL 1:1000; 
re-challenge was not recommended. 
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Radiotherapy was given according to local protocols, with radiotherapy intent 
employed as a stratification factor (planned at randomisation, not planned at 
randomisation). Any endocrine treatment was to be stopped prior to commencing 
chemotherapy, and recommenced as appropriate afterwards according to local 
protocols. The tAnGo trial was completed before adjuvant trastuzumab was used 
routinely and therefore the protocol did not include guidelines for adjuvant 
trastuzumab in HER2 positive patients. Patients could be recruited into the HERA 
Trial12. Clinical surveillance was continued for 10 years at the clinical centres.  
To investigate standard prognostic markers and treatment interactions, routine 
pathology tissue blocks from surgery were retrieved for 2462 of the 3141 eligible 
patients (78%) and were reviewed centrally in Cambridge (EP) for breast cancer 
morphology, tumour grade, histotype and scoring of ER, PR and HER2 on 
immunohistochemistry (IHC). Tissue microarrays (TMAs) were constructed with a 
single 0·6mm core from a representative part of the tumour (172 sample arrayed in 
each TMA block) and sections stained for ER, PR and HER2 by IHC, with additional 
FISH for those in the HER2, 2+ category. When central testing was not available 
(22%), results from the local report were included for the biomarker analysis. 
 
Outcomes 
The primary outcome measure of DFS was calculated from date of randomisation to 
date of first relapse (loco-regional or distant, not including DCIS); to date of death in 
women dying without relapse; or to date of censor in women alive and relapse-free. 
The secondary outcome of overall survival was calculated from date of 
randomisation to date of death, or date of censor if alive. 
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Cardiac, pulmonary and hepatic function were initially monitored at four time points 
(randomisation, mid-chemotherapy, post-chemotherapy and 6-months post-
chemotherapy) and showed the treatment regimens as equally well tolerated, only 
causing mild to moderate reduction in pulmonary function, which recovered 
completely by 6 months, and gemcitabine causing increased levels of liver 
transaminases but no adverse clinical events10. For the evaluation of long-term 
toxicity, these assessments were also undertaken at 5 and 10 years post-treatment. 
 
Statistical Analysis 
The original sample size calculations for tAnGo assumed a 5-year DFS of 45-55% 
from patients randomised onto the control arm of the trial, given that all patients were 
to be ER negative. Using this, 3000 patients were deemed necessary to detect (with 
5% two-sided significance,) differences in survival rates in excess of 5% with 80% 
power. This would also allow detection of differences in excess of 7% with 85% 
power and in excess of 10% with 99% power. 
 
When the eligibility criteria for tAnGo were changed in September 2003, to include 
lower risk patients who were ER positive and PgR either positive or unknown, 550 
patients had already been randomized. The effect on the expected 5-year DFS of the 
control arm of the trial was assessed, along with the most up-to-date 5-year DFS 
estimates for early stage breast cancer based on the recent CALGB 9344 and NEAT 
results. Following discussions with the trial Data and Safety Monitoring Committee 
(DSMC), it was determined that the 5-year DFS estimate for control arm patients 
was approximately 70% and that the power of the study to detect in excess of 5% 
 Page 15 
differences with 5% two-sided significance had in fact increased from 80% to 85%. 
tAnGo thus continued to aim for the 3000 patient target. 
 
Survival curves were constructed using Kaplan-Meier methodology. Log-rank tests 
assessed differences in patient and tumour characteristics, and treatment.  Cox-
proportional hazards modelling investigated and adjusted for prognostic factors.  
Hazard ratios of treatment effects on the risk of relapse and death were calculated 
for prognostic subgroups and displayed as forest plots. Secondary outcome 
measures were adverse effects and dose intensity. An additional log-rank analysis 
was undertaken censoring non-breast-cancer deaths at date of death, to assess the 
sensitivity of the DFS and OS results. 
 
The maximum Common Toxicity Criteria (CTC) grades for a list of common toxicities 
reported for all patients during their chemotherapy was examined. 
 
The methods for dose intensity calculations have previously been described13. We 
compared course delivered dose intensities (CDDI) across treatment groups with 
Wilcoxon rank sum tests and chi-squared tests with continuity corrections. 
 
Using Pocock’s method of assigning equal weighting to the alpha spend, with 
significance determined by p=0·02214, three event driven, primary endpoint analyses 
were planned: the first at 18 months minimum follow-up (min FU, 280 events 
expected) allowing detection of differences in excess of 10% with 95% power; the 
second at 30 months min FU (550 events expected) allowing detection of differences 
in excess of 7% with 95% power; the third at 60 months min FU (920 events 
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expected) allowing detection of differences in excess of 5% with 90% power. The 
protocol did not set out rules for stopping the trial early due to futility during the 
recruitment phase. However, through the course of the trial, the TMG and DSMC 
defined and agreed on the plans for stopping rules for futility. These included the 
pre-defined acceptable limit of the conditional power analyses to be undertaken at 
the interim analyses time-points. 
 
 
In June 2006, the tAnGo DSMC scrutinised the first pre-planned primary endpoint 
analysis and considered it too early to release the results. In November 2007, the 
second pre-planned analysis showed the conditional power15 was 7%, below the 10-
15% level pre-set by the DSMC thus making it very likely that the final results would 
be consistent with the current results. The DSMC therefore recommended the trial 
data be released and they were presented at ASCO 200811. Results of the third and 
final pre-planned primary endpoint analysis (minimum 60 months FU, 920 events 
expected) are presented here. 
 
Statistical analysis was undertaken by Warwick Clinical Trials Unit, using SAS 
statistical software (version 9·4). All reported p-values are two-sided. All patients 
who were protocol violators were analysed within their randomised groups thus 
allowing analysis to be undertaken on an intention-to-treat basis. tAnGo is registered 
with ISRCTN (51146252), EudraCT (2004-002927-41), and ClinicalTrials.gov 
(NCT00039546). 
 
Role of the funding source 
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The trial was endorsed by Cancer Research UK and supported by CRUK Clinical 
Trials Unit at University of Birmingham core infrastructure and a grant from Breast 
Cancer Relief. In addition unrestricted educational grants were provided by Eli Lilly 
and Company Limited, Pfizer Limited and Bristol-Myers Squibb Pharmaceuticals 
Limited. Gemcitabine (GemzarTM) and Paclitaxel (TaxolTM) were provided free of 
charge by Eli Lilly and Company Limited and Bristol-Myers Squibb Pharmaceuticals 
Limited respectively. Neither the sponsors of the study nor the pharmaceutical 
companies had any role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding authors (HE and LH) had 
full access to all of the data and (with CJP) had final responsibility for the decision to 
submit for publication. 
 
RESULTS 
Patients  
tAnGo recruited 3152 patients from 175 clinicians at 127 centres in the UK and 
Ireland between 22nd August 2001 and 26th November 2004. Eleven patients (0·3%) 
were ineligible for the trial (6 EC-GT, 5 EC-T), principally for pre-existing metastases 
found after randomisation, leaving 3141 eligible patients for analysis (Figure 1). The 
discovery of the 11 patients’ ineligibility for the trial was independent of the individual 
patient’s randomisation allocation. Patient characteristics, type of operation, timing of 
surgery (Table 1) and tumour characteristics (p.1 Appendix) for the 3141 eligible 
patients (1570 EC-GT, 1571 EC-T) appear balanced between the two treatment 
groups. 
 
Treatment Compliance 
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Protocol violations in treatment allocation were noted by the trial management 
committee in 19 patients (0·6% of 3141, 7 (0·4%) EC-GT, 12 (0·8%) EC-T) (Figure 
1). All analyses included these patients in their original randomised treatment group, 
according to the intention-to-treat principle. 
 
Use of other first-line treatments 
Of the 287 pts known to be HER2 positive, 118 (41%) were reported, at some point 
on their FU forms, to have received trastuzumab (54 EC-GT pts (40% of 135), 64 
EC-T pts (42% of 152)), of which 60/287 (21%) received trastuzumab as adjuvant 
treatment and 58/287 (20%) for relapsed disease. At baseline, radiotherapy was 
planned to be administered in 90% of patients (2823/3141; 90% (1412/1570) of EC-
GT patients, 90% (1141/1571) of EC-T patients). Radiotherapy administration is 
unknown in 15 patients. In the remaining 3126 patients, 2754 (88%) are recorded as 
having received radiotherapy treatment. Rates are equal across treatment arms 
(1378 (88%) EC-GT patients and 1376 (88%) EC-T patients receiving radiotherapy, 
p=0·99). In terms of adjuvant hormonal treatment for ER-positive patients, the follow 
up data indicates that the guidance detailed in Methods was followed, and the 
majority received 5 years of tamoxifen. 
 
Disease-Free and Overall Survival 
At the data lock on 29th September 2016, 914 patients had died (29% of the 3141 
eligible patients; 459/1570 (29%) EC-GT patients; 455/1571 (29%) EC-T patients: 
Figure 1). Breast cancer was listed most frequently as the main cause of death 
(792/914 (87%), p. 2 Appendix), but for the 122 patients for whom breast cancer was 
not listed as the main cause of death, 40/122 (33%) had already had a breast cancer 
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relapse. Therefore 82 patients (9% of 914) died without evidence of recurrent breast 
cancer. The median follow-up for the 2227 pts recorded as being alive was 10 years 
(IQR 10-10 years), with 96% having more than 8 years follow-up. Loco-regional 
and/or distant relapse was recorded in 995 (32%) women (31% EC-GT, 32% EC-T), 
with distant metastases being predominantly in the bone, liver and/or lung. There 
were 1087 events (35% of 3141 patients; 538/1570 (34%) EC-GT; 549/1571 (35%) 
EC-T) in the analysis of DFS. 213 patients (7% of 3141; 109/1570 (7%) EC-GT; 
104/1571 (7%) EC-T) had second primaries recorded. 
 
There was no significant difference between treatment groups in terms of DFS (log-
rank p=0·63, adjusted hazard ratio (HR) 0·97 (95%CI 0·86-1·10), adjusted p=0·64, 
Figure 2a). DFS rates at 2, 5 and 10-years were similar for EC-GT and EC-T patients 
(2-year 88% vs 87%; 5-year 75% vs 74%; 10-year 65% vs 65% respectively). There 
were also no significant differences between treatment groups observed in OS (log-
rank p=0·85, adjusted HR 1·02 (95%CI 0·89-1·16), adjusted p=0·81, Figure 2b). OS 
rates at 2, 5 and 10-years were similar for EC-GT and EC-T patients (2-year 93% vs 
94%; 5-year 82% vs 82%; 10-year 70% vs 71% respectively). A sensitivity analysis 
of breast cancer-specific survival across treatment groups, analysing the 792 deaths 
due to breast cancer showed similar results (389 EC-GT, 403 EC-T), log-rank 
p=0·66, adjusted HR 0·97 (95%CI 0·85-1·12), adjusted p=0·71). 
 
Univariate analysis showed that the following were significantly associated with 
worse DFS: higher nodal burden, negative ER/PR status, radiotherapy planning, 
larger tumour size, higher tumour grade, the presence of vascular/lymphatic 
invasion, mastectomy (all p<0·0001), poorer ECOG performance status (p=0·004), 
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positive HER2 status (p=0·0026), and triple negative phenotype (p=0·01) (Table 2). 
Similar results were found for OS (p.3 Appendix). 
 
Plots of hazards over time for DFS and OS highlighted the similarity of the two 
randomised treatment arms (p.4 and 5 Appendix). However, in an exploratory 
analysis, for the HER2 negative patients, we demonstrated the expected significant 
differences between the ER negative sub-group (TNBC) and the ER positive 
subgroup in hazards over time; TNBC patients showed increased hazards for 
relapse and death in the early years, with a plateau of risk between 5 and 10 years, 
whilst ER positive patients showed persisting, albeit lower risks, for relapse and 
death at 10 years. In the smaller HER2 positive group ER negative and ER positive 
sub-groups showed a similar pattern of changes with increased risk of relapse in the 
early years for both, although higher hazards for ER negative patients. Of note, only 
21% of HER2 positive patients received adjuvant trastuzumab. 
 
Interaction of Treatment Effect with Prognostic Factors 
Forest plots confirmed the lack of treatment effect on DFS in all subgroups of 
patients, specifically by age, ER, PR, nodal and HER2 status, performance status, 
surgery, tumour size, grade, and presence or absence of vascular or lymphatic 
invasion, triple negative status and ER/PGR negative status (Figure 3a-3c). 
Additionally no significant interactions with treatment effect were noted for these 
variables. Similar results were obtained for overall survival (p.6-8 Appendix). A non-
pre-planned analysis was also carried out by four subgroups defined in the Neo-
tAnGo manuscript9 using Grade 3 patients only and splitting by ER combined with 
HER2 status. These four subgroups showed significant heterogeneity in DFS 
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(p=0·02) and borderline heterogeneity in OS (p=0·06), with a numerical trend for 
benefit from gemcitabine in the ER-/HER2+/G3 and ER-/HER2-/G3 subgroups 
(Figure 3c and p.8 Appendix). 
 
Adverse Effects of Chemotherapy 
Information regarding adverse effects was available from 3132 patients with full sets 
of treatment forms returned (99·7% of the 3141 eligible patients). Frequencies of 
patients reporting grades 3 and 4 toxicities are as expected (Table 3). Grade 3 (G3) 
toxicities were reported more commonly with EC-GT (1565pts) than EC-T (1567pts) 
for neutropenia (323 (21%); 212 (14%)): muscle and joint pains (200 (13%); 175 
(11%)): fatigue (200 (13%); 140 (9%): infection (194 (12%); 131 (8%)): vomiting (134 
(9%); 101 (6%)): nausea (132 (8%); 102 (7%)): neuropathy (83 (5%); 66 (4%)): fever 
(69 (4%); 46 (3%)): diarrhoea (43 (3%); 29 (2%)): constipation (41 (3%); 24 (2%)): 
anaemia (27 (2%); 11 (1%)): deep venous thrombosis (17 (1%); 9 (1%)): and 
thrombocytopenia (14 (1%; 7 (<1%)). G3 toxicities were similar in both arms (3132 
pts) for dyspnoea (67 (2%)); stomatitis (56 (2%)): rash (46 (1%)); as was the only 
significant G4 toxicity, neutropenia (404 (13%)).  83/1565 (5%) of EC-GT patients 
discontinued chemotherapy for drug related toxicity and 45/1567 (3%) EC-T patients. 
 
In total, 1158 serious adverse events (SAEs) were reported (650 during EC, 136 
during T and 372 during GT cycles), involving 816 (26% of 3141) patients (474 (30% 
of 1570) EC-GT patients, 342 (22% of 1571) EC-T patients). 1121 (97%) of these 
were evaluated as serious adverse reactions (SARs), involving 794 (25% of 3141) 
patients. There were 31 suspected unexpected serious adverse reactions (SUSARs) 
recorded (20 by EC-GT patients, 11 by EC-T patients). 
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Detailed Safety Sub-study – Long-term toxicity assessments 
There were 135 patients (69 EC-GT, 66 EC-T) included in the detailed safety sub-
study. The assessment completion rate at 5-years post treatment was 75% (73 of 
the 97 patients alive; 72% EC-GT (34 of the 47 alive) and 78% EC-T (39 of the 50 
alive)). At 10-years, assessment completion rates were 74% (63 of the 85 patients 
alive; 78% EC-GT (31 of the 40 alive) and 71% EC-T (32 of the 45 alive)). In total, 49 
patients completed all 6 assessments (58% of the 85 alive at 10-years; 25 (63%) 
EC-GT, 24 (53%) EC-T). There were no long-term safety signals of significant 
concern (p.9 Appendix). 
 
Early Deaths 
19 patients (0·6% of the 3141 eligible patients) died within 3 months of completing 
their last chemotherapy cycle (10 (0·6% of 1570) EC-GT, 9 (0·6% of 1571) EC-T). 14 
of these patients (7 EC-GT, 7 EC-T) died with metastatic breast cancer more than 30 
days after day 1 of their last chemotherapy cycle and this indicates that they were 
likely to have had metastatic disease at the time of randomisation. In addition, one 
EC-T patient died of a second primary lung cancer and one EC-GT patient by 
suicide. Chemotherapy possibly contributed to 3 deaths: one (EC-GT) with breast 
cancer on day 18, cycle 2 from venous thrombo-embolism (VTE); one (EC-T) died 
from VTE 41 days after day 1, cycle 3; and one (EC-GT) from ischaemic heart 
disease 28 days after day 1 of cycle 2. 
 
Dose Intensity 
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Complete information for dose intensity calculations was available on 3137 of the 
3141 eligible patients (99·9%). EC-GT patients received moderately lower course-
delivered dose intensity (CDDI) than EC-T patients (median (IQR) 96% (88-99) vs 
98% (93-100), p<0·0001). Additionally, fewer EC-GT patients received CDDI >85% 
(80% (1261/1568) vs 89% (1395/1569), for EC-T patients, p<0·0001). 
 
DISCUSSION 
The tAnGo trial showed no benefit in either DFS or OS from the addition of 
gemcitabine to standard paclitaxel-containing, epirubicin/cyclophosphamide-based 
adjuvant chemotherapy in early breast cancer whereas toxicity was increased with 
more grade 3 myelosuppression, fatigue, and infection. We have the benefit of data 
from the tenth annual follow-up on 2121 patients (95% of the 2227 known to be 
alive) and therefore the results for all stratified risk groups are robust and are not 
unduly biased by length of follow-up16. The tAnGo trial was an all-comers trial carried 
out before the standard use of adjuvant trastuzumab for HER2 positive disease. At 
the start of the trial, adjuvant chemotherapy in the UK included paclitaxel for high-risk 
disease in very few centres. With the intention of ensuring that the results of the trial 
would be relevant in the future, we included paclitaxel in the standard arm, and at the 
start of the trial recruited only ER-negative and ER weakly positive patients, 
representing the highest risk population. In the second part of the trial the entry 
criteria were expanded to include moderate risk patients, because of emerging 
evidence at that point for more routine use of adjuvant taxanes5,6. The tAnGo trial 
was one of the last all-comers trials of its type in the UK and since then breast 
cancer type specific trials have been more frequent. The advantages of the 
permissive entry criteria used included rapid patient recruitment. 
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It is difficult to explain why the overall results were negative for adjuvant gemcitabine 
when the drug had been so promising in the metastatic setting17, particularly given 
the ongoing positive results in metastatic TNBC18. Gemcitabine has recently been 
included in an international trial in metastatic TNBC with carboplatin and nab-
paclitaxel19,. The first results of the Phase 2 feasibility study were presented at the 
San Antonio Breast Cancer Symposium in December 201620, and showed no benefit 
from the addition of gemcitabine. In view of this the trial (tnAcity study) will not 
proceed to a randomised phase III study.  However there have been positive results 
in other solid tumours most notably pancreatic cancer21. Perhaps the addition of a 
fourth drug to three effective drugs is simply not going to improve DFS and OS in 
early breast cancer. The companion neoadjuvant trial (Neo-tAnGo) also showed no 
increase in pathological complete response (pCR) rate with the addition of 
gemcitabine and no improvement in DFS and OS22. In addition, neither the 
neoadjuvant NSABP-B4022,23 trial examining both capecitabine and gemcitabine 
added to paclitaxel, nor the adjuvant NSABP-B388 using AC-TG as one of the 
experimental arms, showed any improvement in pCR or DFS and OS. 
 
Since gemcitabine, an anti-metabolite, is in the same class of drugs as capecitabine, 
recent data on that drug is of interest. The adjuvant TACT 2 trial demonstrated that 
capecitabine has some advantages over standard CMF following anthracycline-
based treatment [submitted, February 2017], because of lower toxicity and better 
quality of life with no apparent loss of efficacy. However, when capecitabine was 
added to docetaxel, doxorubicin and cyclophosphamide in the FINNXX trial23, there 
was no improvement in DFS and when capecitabine was substituted for 
cyclophosphamide in the GEICAM/2003-10 Study there was an increase in DFS 
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events24. Nevertheless, there has been a recent renewal of interest with the use of 
capecitabine after neoadjuvant chemotherapy in patients who had not achieved a 
pCR in the CREATE-X study25. The benefits of this adjuvant treatment, were 
significant and most marked in the TNBC group (296 patients: HR 0·58 [95% CI 
0·39-0·87]). However, it is unlikely that gemcitabine could be used in this setting 
because of the significantly higher toxicity particularly myelosuppression. 
 
Are there potential subgroups in tAnGo in which increased benefit from adjuvant 
gemcitabine could be further explored? Two groups identified are the ER-negative/ 
grade3, HER2 positive or negative subsets (Figure 3c and p.8 Appendix)), which 
also showed a possible benefit for pCR in Neo-tAnGo22. Recent preclinical research 
has reported compelling results of relevance to gemcitabine use in breast cancer26, 
showing that mutant p53 (mtp53) harbouring cells are highly sensitive to the cell 
killing effects of gemcitabine via inhibition of deoxycytidine kinase (dCK). In addition, 
dCK and/or p53 knockdown of these cells, abrogating the gain-of-function, conferred 
relative resistance to gemcitabine but not to cisplatin or doxorubicin. mtp53 status 
has been shown to be related to poor prognosis in breast cancer patients27 and was 
recently studied in GEPAR SIXTO28. mtp53 was present in 297/450 (66%) patients, 
more frequently in TNBC (184/246 [74·8%]) compared to HER2-positive cancers 
(113/204 [55·4%] p<0·0001). As part of the tAnGo and Neo-tAnGo studies we have 
collected 80% of FFPE tumour samples for translational research and plan to 
explore this preclinical data further. 
 
So what of the limitations of the tAnGo trial? Although a negative study, this is not 
itself a limitation and the study was carried out adhering to all the international 
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guidelines and governance for phase 3 randomised trials. The major limitation seen 
from the perspective of 2017 was the inclusion of all prognostic and biomarker 
subgroups in the same trial, which would not happen in present day trials. On the 
other hand this can be seen as a strength, because all subgroups were tested for the 
new treatment, and recruitment was more rapid since more patients were eligible. 
Such permissive entry criteria have served us well in the UK, and resulted in good 
and rapid recruitment to this and similar contemporaneous trials. The most important 
strength now is the minimum of 10 years follow-up and therefore the robustness of 
the (albeit negative) results.  
In summary, the tAnGo, Neo-tAnGo, NSABP-B38 and NSABP-B40 trials all 
demonstrate a lack of activity when gemcitabine is added to three potent 
neo/adjuvant breast cancer chemotherapy drugs. tAnGo was a large, rapidly 
recruiting trial with sufficient follow up to allow confidence in this result. Parallel 
translational science for tAnGo is ongoing, including tumour genomic analysis, 
pharmacogenetics29,30 and inherited predisposition analyses31. Clinical trials 
datasets, painstakingly collected and analysed, clearly need to be published fully 
including all negative studies. The publication of a ‘negative’ trial is as important for 
patients and the clinical research community as the positive trial results which lead to 
licensing approvals or change of practice that are generally perceived as more 
valuable. The rejection of gemcitabine from standard adjuvant breast cancer 
treatment for lack of benefit can be seen as a cost-effective result in terms of both 
financial and patient toxicity costs. 
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CONCLUSION 
Gemcitabine in combination with paclitaxel after epirubicin and cyclophosphamide is 
not indicated in adjuvant breast cancer treatment with current biological 
characterisation. However, it seems likely that further improvements in the outcome 
of treatment for women with early breast cancer will depend on the development of 
targeted therapies, whose selective application is predicated on the biological 
heterogeneity of this disease. 
 
RESEARCH IN CONTEXT 
Evidence before this study 
Gemcitabine had been used in metastatic breast cancer with significant benefit. The 
tAnGo trial which started in 2001, tested the addition of gemcitabine to standard 
anthracycline and taxane-based chemotherapy in the adjuvant treatment of early 
breast cancer. NSABP-B38 was the only other adjuvant breast cancer trial which 
added gemcitabine to standard chemotherapy. Two neoadjuvant breast cancer 
studies were undertaken: NeotAnGo was the companion study to tAnGo, which in a 
2x2 factorial design tested both the addition of gemcitabine and taxane-first 
sequencing; and NSABP-B40 which in a 2x3 factorial design tested the addition of 
either gemcitabine or capecitabine, and also bevacizumab. 
 
Added Value of this study 
Early results from the tAnGo trial presented in 2008 showed no benefit in terms of 
DFS and OS and in this manuscript we report trial outcomes with a median follow-up 
of ten years. We demonstrate no benefit from the addition of gemcitabine to standard 
adjuvant chemotherapy in any prognostic sub-group. Recent pre-clinical research 
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suggests that gain-of-function mutations in TP53 may confer sensitivity to 
gemcitabine. 
 
Implications of all the available evidence 
Since the start of this trial the benefit of the addition of taxanes has been confirmed 
by the Early Breast Cancer Trialists’ Collaborative Group overview. However, all 
neo/adjuvant clinical trials (tAnGo, Neo-tAnGo, NSABP-B38 and NSABP-B40) in 
early breast cancer show no advantage for the addition of gemcitabine to standard 
anthracycline and taxane-based chemotherapy. No sub-group has been identified 
showing gemcitabine benefit. Pre-clinical data suggesting gemcitabine sensitivity 
with TP53 gain-of-function mutations will be explored in the tAnGo translational 
tumour bank resource. 
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FIGURE Legends 
Figure 1: Trial Profile 
Figure 2: Disease-free survival and overall survival by treatment group 
Figure 3: Disease-Free Survival by Treatment, split by prognostic factors 
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Table 1: Patient Characteristics 
  EC-GT 
(n=1570) 
EC-T  
(n=1571) 
  N % N % 
* Randomising Country                   England 1282 81 1283 81 
 Scotland 189 12 185 12 
 Wales 66 4 72 4 
 Republic of Ireland 30 2 27 2 
 Northern Ireland 3 1 4 1 
      
* Age                                       <50 years old 862 55 867 55 
 >50 years old 708 45 704 45 
      
* ER Status                                    Negative 692 44 686 44 
 Weakly-positive 168 11 197 12 
 Positive 710 45 688 44 
      
 PgR Status                                  Negative 695 44 703 45 
 Weakly-positive 181 12 165 11 
 Positive 524 33 510 32 
 Unknown 170 11 193 12 
      
* Nodal Status                                Negative 364 23 362 23 
 1-3 nodes positive 648 41 646 41 
 >4 nodes positive 558 36 563 36 
      
* Radiotherapy planned                         Yes 1412 90 1411 90 
 No 158 10 160 10 
      
      
* HER2 status                                        +++ 135 9 152 10 
 Other (0, 1+, 2+) 1015 64 990 63 
 Unknown 420 27 429 27 
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 ECOG performance status                      0 1433 91 1464 93 
 1 135 8 106 6 
 2 2 1 1 1 
      
 Menopausal Status                              Pre 728 46 701 45 
 Peri 104 7 131 8 
 Post 560 36 556 35 
 Bilateral Oophorectomy 14 1 12 1 
 Hysterectomy 87 5 106 7 
 Unknown 77 5 65 4 
      
 Definitive Surgery                   Mastectomy 874 56 875 56 
 Breast Conserving Surgery 696 44 696 44 
      
 Days from Definitive Surgery to Entry     N 1570 1571 
 Median (IQR) 31 (24 – 40) 32 (25 – 41) 
 Range 6 – 76 -9 – 80 
      
 Triple negatives                                   Yes 364 23 362 23 
 No 1028 66 1031 66 
 Unknown 178 11 178 11 
      
 ER/PGR negatives                              Yes 561 36 562 36 
 No 955 61 946 60 
 Unknown 54 3 63 4 
* Stratification variables at randomisation 
^ 2 patients were randomised prior to definitive surgery, after authorisation from 
the Chief Investigator   
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Table 2: Disease-Free Survival according to treatment, patient and tumour characteristics 
 No. of 
patients* 
No. of 
Events 
p-value DFS rates % (95% CI) 
Variable 2 year 5 year 10 year 
Overall 3141 1087  88 (86-89) 75 (73-76) 65 (63-67) 
       
Treatment group   0·63    
EC-GT 1570 538  88 (87-90) 75 (73-77) 65 (63-68) 
EC-T 1571 549  87 (85-88) 74 (72-76) 65 (62-67) 
       
Number of nodes involved   <0·0001    
        0 726 147  93 (91-95) 86 (84-89) 79 (76-82) 
        1-3 1294 378  91 (89-92) 79 (76-81) 71 (68-73) 
        4+ 1121 562  80 (77-82) 62 (59-65) 50 (47-53) 
       
Oestrogen-receptor status   <0·0001    
        Negative  1378 513  82 (79-83) 69 (66-71) 62 (60-65) 
        Weakly-positive 365 130  86 (82-89) 74 (70-79) 64 (59-69) 
        Positive 1398 444  94 (92-95) 80 (78-82) 68 (66-71) 
       
Progesterone-receptor status   <0·0001    
        Negative  1398 517  83 (81-85) 69 (66-71) 63 (60-65) 
        Weakly-positive 346 129  87 (83-90) 74 (69-78) 62 (57-67) 
        Positive 1034 312  94 (93-96) 83 (80-85) 70 (67-72) 
       
Radiotherapy planned   <0·0001    
       Yes 2823 1012  87 (85-88) 73 (72-75) 64 (62-66) 
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       No 318 75  95 (92-97) 86 (82-89) 76 (71-80) 
       
Tumour size   <0·0001    
        <2cm 1122 280  92 (90-93) 82 (80-85) 75 (72-77) 
        >2 and <5cm 1663 648  86 (84-88) 71 (69-73) 61 (58-63) 
       >5cm 266 133  77 (71-81) 61 (55-67) 49 (43-55) 
       
Tumour Grade   <0·0001    
Well differentiated 49 10  100 (100-100) 94 (82-98) 79 (65-88) 
        Moderately differentiated 1141 355  92 (91-94) 80 (78-83) 69 (66-71) 
        Poorly differentiated 1948 722  84 (83-86) 71 (69-73) 63 (60-65) 
       
Vascular/Lymphatic invasion   <0·0001    
        Reported 1836 752  84 (82-85) 69 (67-71) 59 (57-61) 
        Unreported 1303 335  93 (91-94) 82 (80-84) 74 (72-76) 
       
Surgery   <0·0001    
        Mastectomy 1749 673  86 (84-87) 72 (69-74) 61 (59-64) 
        Breast Conserving Surgery 1392 414  90 (88-91) 78 (76-80) 70 (67-72) 
       
ECOG performance status   0·004    
        0 2897 983  88 (87-89) 75 (74-77) 66 (64-68) 
        1 or 2 244 104  84 (79-88) 67 (60-72) 57 (51-63) 
       
HER-2 status   0·0026    
        +++ 287 119  82 (77-86) 66 (60-71) 58 (52-64) 
        Other 2005 679  88 (87-90) 76 (74-78) 66 (64-68) 
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Age   0·80    
        <50 years old 1729 596  87 (85-88) 73 (71-75) 65 (63-67) 
        >50 years old 1412 491  88 (86-90) 76 (74-78) 65 (63-68) 
       
Menopausal status   0·86    
        Pre  1429 489  88 (86-89) 74 (71-76) 65 (63-68) 
       Peri 235 80  89 (84-92) 76 (70-81) 66 (59-71) 
        Post 1116 397  87 (85-89) 76 (73-78) 64 (61-67) 
       
Triple negatives   0·01    
Yes 726 266  81 (78-84) 69 (65-72) 63 (59-66) 
No 2059 695  91 (89-92) 77 (75-79) 66 (64-68) 
       
ER/PGR negative   0·0008    
Yes 1123 412  81 (79-84) 69 (66-71) 63 (60-66) 
No 1901 626  92 (90-93) 78 (77-80) 67 (65-69) 
* Patients with missing data for a given variable were excluded from the analysis of that variable 
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Table 3: Maximum reported grades of Adverse Effects during treatment by 3132 patients 
 EC-GT (n=1565) EC-T (n=1567) 
 1/2 3 4 1/2 3 4 
Neutropenia  397 (25%) 323 (21%) 204 (13%) 364 (23%) 212 (14%) 200 (13%) 
Myalgia/arthralgia 1140 (73%) 200 (13%) 7 (<1%) 1147 (73%) 175 (11%) 11 (1%) 
Fatigue  1254 (80%) 198 (13%) 9 (1%) 1287 (82%) 140 (9%) 12 (1%) 
Infection  578 (37%) 194 (12%) 8 (1%) 601 (38%) 131 (8%) 10 (1%) 
Vomiting  786 (50%) 134 (9%) 9 (1%) 736 (47%) 101 (6%) 7 (1%) 
Nausea 1271 (81%) 132 (8%) - 1255 (80%) 102 (7%) - 
Neuro-sensory 1133 (72%) 83 (5%) 2 (<1%) 1174 (75%) 66 (4%) 3 (<1%) 
Fever 332 (21%) 69 (4%) 1 (<1%) 235 (15%) 46 (3%) 3 (<1%) 
Diarrhoea 648 (41%) 43 (3%) 1 (<1%) 607 (39%) 29 (2%) 0 
Constipation 1086 (69%) 41 (3%) 1 (<1%) 1099 (70%) 24 (2%) 0 
Dyspnoea 485 (31%) 37 (2%) 3 (<1%) 423 (27%) 30 (2%) 3 (<1%) 
Stomatitis 1119 (72%) 31 (2%) 0 1095 (70%) 25 (2%) 0 
Anaemia 873 (56%) 27 (2%) 1 (<1%) 629 (40%) 11 (1%) 3 (<1%) 
Skin 703 (45%) 25 (2%) 0 651 (42%) 20 (1%) 1 (<1%) 
DVT 4 (<1%) 17 (1%) 3 (<1%) 2 (<1%) 9 (1%) 3 (<1%) 
Thrombocytopenia 130 (8%) 14 (1%) 4 (<1%) 75 (5%) 7 (<1%) 2 (<1%) 
Cough 570 (36%) 10 (1%) - 526 (34%) 4 (<1%) - 
Superficial 
Thrombophlebitis 
367 (23%) 7 (<1%) 0 329 (21%) 1 (<1%) 1 (<1%) 
Alopecia 1525 (97%) - - 1527 (97%) - - 
No grade 5 adverse events were reported. 
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Figure 3a: Disease-Free Survival by Treatment, split by prognostic factors (1)
Events/Patients
EC-GT EC-T
EC-GT events
(O-E) Var
*Hazard Ratio & CI
(EC-GT : EC-T)
*HR & CI
(EC-GT : EC-T)
.1 .2 .3 .4 .5  2  3  4  5 10
EC-GT better EC-T better
* 95% CI99% CI
Age
<=50 291/862 305/867   -8.5  149.0
(33.8%) (35.2%)
0.94 (0.76, 1.17)
>50 247/708 244/704    0.6  122.7
(34.9%) (34.7%)
1.01 (0.80, 1.27)
Stratified 538/1570 549/1571   -7.9  271.7(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.63)
   = 0.3; P=.61  Interaction between 2 groups 21
ER
Negative 248/692 265/686  -10.5  128.2
(35.8%) (38.6%)
0.92 (0.73, 1.16)
Weakly Positive 59/168 71/197   -1.8   32.3
(35.1%) (36.0%)
0.95 (0.60, 1.49)
Positive 231/710 213/688    5.1  110.9
(32.5%) (31.0%)
1.05 (0.82, 1.34)
Stratified 538/1570 549/1571   -7.2  271.5(34.3%) (34.9%) 0.97 (0.86, 1.10)(P=.66)
   = 1.0; P=.32Test for trend over 3 groups 21
PGR
Negative 252/695 265/703   -6.7  129.2
(36.3%) (37.7%)
0.95 (0.76, 1.19)
Weakly positive 69/181 60/165    2.6   32.2
(38.1%) (36.4%)
1.08 (0.69, 1.71)
Positive 165/524 147/510    8.0   78.0
(31.5%) (28.8%)
1.11 (0.83, 1.48)
Stratified 486/1400 472/1378    3.9  239.4(34.7%) (34.3%) 1.02 (0.90, 1.15)(P=.80)
   = 1.2; P=.27Test for trend over 3 groups 21
Node
Negative 72/364 75/362   -1.0   36.7
(19.8%) (20.7%)
0.97 (0.64, 1.49)
1-3 positive 191/648 187/646   -1.3   94.5
(29.5%) (28.9%)
0.99 (0.76, 1.29)
4+ Positive 275/558 287/563   -5.5  140.5
(49.3%) (51.0%)
0.96 (0.77, 1.19)
Stratified 538/1570 549/1571   -7.8  271.7(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.64)
   = 0.0; P=.89Test for trend over 3 groups 21
HER2
+++ 55/135 64/152   -1.5   29.7
(40.7%) (42.1%)
0.95 (0.59, 1.53)
Other 350/1015 329/990    6.4  169.7
(34.5%) (33.2%)
1.04 (0.85, 1.27)
Stratified 405/1150 393/1142    4.9  199.4(35.2%) (34.4%) 1.03 (0.89, 1.18)(P=.73)
   = 0.2; P=.66  Interaction between 2 groups 21
Unstratified 538/1570 549/1571   -7.9  271.7(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.63)
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Figure 3b: Disease-Free Survival by Treatment, split by prognostic factors (2)
Events/Patients
EC-GT EC-T
EC-GT events
(O-E) Var
*Hazard Ratio & CI
(EC-GT : EC-T)
*HR & CI
(EC-GT : EC-T)
.1 .2 .3 .4 .5  2  3  4  5 10
EC-GT better EC-T better
* 95% CI99% CI
Performance Status
0 483/1433 500/1464   -6.0  245.7
(33.7%) (34.2%)
0.98 (0.83, 1.15)
1 / 2 55/137 49/107   -3.6   25.6
(40.1%) (45.8%)
0.87 (0.52, 1.45)
Stratified 538/1570 549/1571   -9.6  271.3(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.56)
   = 0.3; P=.57  Interaction between 2 groups 21
Surgery
Mastectomy 338/874 335/875    1.5  168.2
(38.7%) (38.3%)
1.01 (0.83, 1.23)
Breast Conserving 200/696 214/696   -8.9  103.5
(28.7%) (30.7%)
0.92 (0.71, 1.18)
Stratified 538/1570 549/1571   -7.4  271.7(34.3%) (34.9%) 0.97 (0.86, 1.10)(P=.65)
   = 0.6; P=.45  Interaction between 2 groups 21
Tumour Size
<=2cm 127/540 153/582   -8.4   69.9
(23.5%) (26.3%)
0.89 (0.65, 1.21)
>2 - <=5cm 330/840 318/823    0.9  162.0
(39.3%) (38.6%)
1.01 (0.82, 1.23)
>5 cm 67/139 66/127   -3.5   33.1
(48.2%) (52.0%)
0.90 (0.58, 1.41)
Stratified 524/1519 537/1532  -11.0  265.0(34.5%) (35.1%) 0.96 (0.85, 1.08)(P=.50)
   = 0.1; P=.73Test for trend over 3 groups 21
Grade
Well 7/25 3/24    2.2    2.5
(28.0%) (12.5%)
2.40 (0.47, 12.25)
Mod 172/558 183/583   -2.0   88.7
(30.8%) (31.4%)
0.98 (0.74, 1.28)
Poor 359/986 363/962  -10.1  180.4
(36.4%) (37.7%)
0.95 (0.78, 1.15)
Stratified 538/1569 549/1569   -9.9  271.6(34.3%) (35.0%) 0.96 (0.86, 1.09)(P=.55)
   = 0.5; P=.48Test for trend over 3 groups 21
VL invasion
No 161/662 174/641  -11.5   83.7
(24.3%) (27.1%)
0.87 (0.66, 1.16)
Yes 377/907 375/929    6.7  187.9
(41.6%) (40.4%)
1.04 (0.86, 1.25)
Stratified 538/1569 549/1570   -4.7  271.6(34.3%) (35.0%) 0.98 (0.87, 1.11)(P=.77)
   = 1.7; P=.19  Interaction between 2 groups 21
Unstratified 538/1570 549/1571   -7.9  271.7(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.63)
Figure 3b
Figure 3c: Disease-Free Survival by Treatment, split by prognostic factors (3)
Events/Patients
EC-GT EC-T
EC-GT events
(O-E) Var
*Hazard Ratio & CI
(EC-GT : EC-T)
*HR & CI
(EC-GT : EC-T)
.1 .2 .3 .4 .5  2  3  4  5 10
EC-GT better EC-T better
* 95% CI99% CI
Triple negative
Yes 131/364 135/362   -3.1   66.5
(36.0%) (37.3%)
0.95 (0.70, 1.31)
No 348/1028 347/1031   -0.1  173.7
(33.9%) (33.7%)
1.00 (0.82, 1.22)
Stratified 479/1392 482/1393   -3.2  240.2(34.4%) (34.6%) 0.99 (0.87, 1.12)(P=.84)
   = 0.1; P=.75  Interaction between 2 groups 21
ER/PGR negative
Yes 198/561 214/562   -9.1  103.0
(35.3%) (38.1%)
0.92 (0.71, 1.18)
No 321/955 305/946    6.6  156.5
(33.6%) (32.2%)
1.04 (0.85, 1.28)
Stratified 519/1516 519/1508   -2.5  259.5(34.2%) (34.4%) 0.99 (0.88, 1.12)(P=.88)
   = 1.1; P=.30  Interaction between 2 groups 21
 Grade ER HER2
Gr3 ER pos HER2 neg 110/267 91/255    8.3   50.2
(41.2%) (35.7%)
1.18 (0.82, 1.70)
Gr3 ER pos HER2 pos 18/33 10/40    5.6    6.9
(54.5%) (25.0%)
2.27 (0.85, 6.06)
Gr3 ER neg HER2 pos 22/66 33/65   -6.7   13.7
(33.3%) (50.8%)
0.62 (0.31, 1.23)
Gr3 ER neg HER2 neg 124/361 131/349   -7.2   63.7
(34.3%) (37.5%)
0.89 (0.65, 1.23)
Stratified 274/727 265/709    0.1  134.5(37.7%) (37.4%) 1.00 (0.85, 1.19)(P=.99)
   =10.0; P=.02Heterogeneity between 4 groups 23
Unstratified 538/1570 549/1571   -7.9  271.7(34.3%) (34.9%) 0.97 (0.86, 1.09)(P=.63)
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